Leah Sherwood

Articles by Leah Sherwood

Leah SherwoodIndolent B-Cell Lymphoma | February 22, 2024
Patients with LBCL who received CAR T-cell therapy earlier in treatment had lower occurrences of severe neutropenia.
Read More
Ching-Hon Pui, MDPrint | February 8, 2024
Dr. Pui, of St. Jude Children’s Research Hospital, discusses his lifelong commitment to being a pediatric oncologist.
Leah SherwoodAcute Lymphoblastic Leukemia | January 31, 2024
The past two decades have witnessed a rapid change in the treatment of acute lymphoblastic leukemia.
Leah SherwoodMyeloma | February 2, 2024
The agency's statement follows potential risks identified by the FDA Adverse Event Reporting System.
Leah SherwoodPrint | January 5, 2024
These are the top five most read articles published by Blood Cancers Today.
Leah SherwoodAcute Lymphoblastic Leukemia | January 5, 2024
The approval is based on the clinical results from a single-arm, multicenter, pivotal study in China.
Leah SherwoodTransplantation & Cellular Therapy | January 5, 2024
GVHD affects approximately 30,000 Americans, according to Dr. Michael Chancellor, Chief Medical Officer at Lipella.
Leah SherwoodAcute Myeloid Leukemia | January 5, 2024
The authorization by the European Commission is based on results from the QuANTUM-First trial.
Leah SherwoodChronic Lymphocytic Leukemia | January 5, 2024
Lisocabtagene maraleucel is a CD19-directed CAR T-cell therapy with a 4-1BB co-stimulatory domain.
Leah SherwoodMeeting News | December 18, 2023
DDX3X dysregulation is involved in the progression of CLL by facilitating NOTCH1 mRNA translation
Leah SherwoodMeeting News | December 18, 2023
Researchers said there was a need for potentially more effective one-time-only treatment options.
Leah SherwoodAggressive B-Cell Lymphoma | December 14, 2023
The results were presented at the 65th American Society of Hematology Annual Meeting & Exposition in San Diego.
Leah SherwoodMantle Cell Lymphoma | December 14, 2023
The data came from ZUMA-2, a phase II, open-label, multicenter, single-arm trial in which participants received brexu-cel.
Leah SherwoodMyeloproliferative Neoplasms | December 13, 2023
“Among the high-risk splicing mutations, SRSF2 has the worst prognostic role,” Dr. Braish and colleagues wrote.
Leah SherwoodAcute Myeloid Leukemia | December 6, 2023
Overall, significantly higher rates of ≥8-week, ≥24-week, and ≥1-year RBC-TI were achieved in patients receiving ...
Leah SherwoodAcute Lymphoblastic Leukemia | December 3, 2023
Adding blinatumomab to consolidation chemotherapy represents a new standard of care in newly diagnosed B-lineage ALL.
This issue includes a feature on artificial intelligence in blood cancers and an editorial on treating patients with LR-MDS.
Leah SherwoodPrint | November 13, 2023
Clinicians weigh in on AI advances in hematological diagnoses, prognoses, and treatment.
This issue includes a feature on the wave of bispecific antibody approvals; a Get to Know with Jerald Radich, MD.
Leah SherwoodMeeting News | February 8, 2024
The meeting had more than 2,500 registrants attending in person or online.